Ginsberg H N
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Clin Cardiol. 1995 Jun;18(6):307-15. doi: 10.1002/clc.4960180605.
Numerous studies involving patients with hypercholesterolemia have demonstrated that reduction of lipid levels markedly reduces morbidity and mortality from cardiovascular disease. Diet alone may enable patients without established disease to attain target lipid levels, but pharmacotherapy generally is necessary for those with coronary artery disease. Choice of a suitable agent for monotherapy--a bile acid resin, niacin, or an HMG-CoA reductase inhibitor--may be determined by patient phenotype. For resistant cases, therapy combining an HMG-CoA reductase inhibitor with another agent generally is effective and well tolerated.
大量针对高胆固醇血症患者的研究表明，降低血脂水平可显著降低心血管疾病的发病率和死亡率。仅通过饮食，尚未患心血管疾病的患者或许能够达到血脂目标水平，但对于患有冠状动脉疾病的患者而言，通常需要药物治疗。选择合适的单一治疗药物——胆酸螯合剂、烟酸或HMG-CoA还原酶抑制剂——可依据患者的表型来决定。对于难治性病例，将HMG-CoA还原酶抑制剂与另一种药物联合使用的治疗方法通常有效且耐受性良好。
